Here are Antti’s preview comments as Orion reports its Q4 results on Thursday. 
We expect a very strong finish to 2025 for Orion, driven particularly by the excellent sales performance of the prostate cancer drug Nubeqa. The company already provided preliminary information on the 2026 outlook in January, which suggests that Nubeqa’s success story will continue into the current year.